Connecting the pieces: an update on recent work across life sciences
The past few weeks have been a strong reminder of why I do what I do. It has been a period of intense activity across multiple fronts, from new client collaborations to international engagement and upcoming industry events.
What stands out most is not any single initiative, but how they are starting to connect.
A new collaboration – early breast cancer screening
I have recently started working with a new client focused on early screening for breast cancer.
This is an area where the need is clear. Earlier detection directly translates into better outcomes, yet access to scalable and efficient screening solutions remains a challenge across many healthcare systems.
The work here is focused on helping position the company internationally, including identifying the right environments for early pilot programmes and building connections across clinical, commercial, and community settings.
As part of this, the company will be attending the Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair in May. This creates an important opportunity to engage directly with stakeholders on the ground, from healthcare providers to potential partners and investors.
What is particularly compelling is the opportunity to explore more accessible screening models, including community-based and mobile solutions. This is where innovation can genuinely shift how care is delivered.
Building structured pathways – Market Entry Sprints
Alongside individual projects, I have been developing a more structured approach to internationalisation through focused 4–6 week Market Entry & Validation Sprints.
These are designed for life science companies that are ready to move beyond strategy and into action.
The sprints are built to:
- clarify the right market entry pathway
- identify and prioritise relevant stakeholders
- create targeted introductions and early engagement
- define clear next steps towards pilots, partnerships, or fundraising
The intention is simple. To reduce time to market, de-risk early decisions, and ensure companies are speaking to the right people from the outset.
Contributing to the conversation
Another milestone for me personally has been contributing my first guest column to BioStock.
Gästkrönika: Vägen in i Asien går via Hongkong – Biostock
The piece explores whether Hong Kong can serve as a gateway for Nordic life science companies looking to enter Asia.
It reflects a broader question I am seeing across the industry: how to build international expansion strategies that are not just ambitious, but also realistic and executable.
Moderating BioStock Global Forum – Bubbles & Pitch
I am also looking forward to returning to Medicon Village on 21 May, where I will be moderating the “Bubbles & Pitch” stage at the BioStock Global Forum.
This is always one of the most energising parts of the forum. It brings together innovators addressing real medical needs and gives them a platform to present their solutions to an engaged audience.
It is also where you see the ecosystem in action. Early-stage ideas, commercial ambition, and scientific depth all in one place.
International engagement
Alongside this, I am supporting the coordination of an upcoming international life sciences delegation visiting Sweden in May.
The programme brings together stakeholders across government, academia, and industry, with a focus on strengthening collaboration and creating meaningful exchange across research, clinical development, innovation, and investment.
It is part of a broader shift towards more structured international collaboration, something I believe will become increasingly important for companies looking to scale.
Bringing it together
Across all of this, there is a common thread.
Whether it is supporting a company working on early cancer detection, building structured market entry pathways, contributing to industry dialogue, facilitating international collaboration, or moderating conversations on stage, the goal is the same.
To create the conditions where good ideas can move forward faster and with the right support around them.
Life sciences is one of the few sectors that genuinely operates beyond borders. It requires collaboration, trust, and a shared focus on outcomes that go beyond individual organisations or markets.
That is where I continue to focus my time.
More to come over the next few weeks.
Lucy
